File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1007/s00268-017-4192-3
- Scopus: eid_2-s2.0-85029448058
- PMID: 28905105
- WOS: WOS:000424278600026
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Diagnostic and prognostic role of 18-FDG PET/CT in the management of resectable biliary tract cancer
Title | Diagnostic and prognostic role of 18-FDG PET/CT in the management of resectable biliary tract cancer |
---|---|
Authors | |
Issue Date | 2018 |
Publisher | Springer New York LLC. The Journal's web site is located at http://link.springer.de/link/service/journals/00268/ |
Citation | World Journal of Surgery, 2018, v. 42 n. 3, p. 823-834 How to Cite? |
Abstract | Objectives: Role of 18-FDG PET/CT had been well established in other more prevalent malignancies such as colorectal and lung cancer; however, this is not as well defined in cholangiocarcinoma. Literature focusing on the prognostic values of preoperative PET/CT for resectable cholangiocarcinoma is scarce. Method: This is a retrospective cohort of 66 consecutive patients who had received curative resection for cholangiocarcinoma from 2010 to 2015. All patients had preoperative 18-FDG PET/CT performed. Accuracy of metastatic lymph node detection of PET/CT and the prognostic value of maximum standard uptake value (SUV-max) was explored. Results: There were 38 male and 28 female recruited, and the median age was 66. Intrahepatic cholangiocarcinoma (ICC) constituted the majority (59.1%) of the cases, followed by hilar cholangiocarcinoma (22.8%), gallbladder cancer (13.6%) and common bile duct cancer (4.5%). The 3-year disease-free survival (DFS) and overall survival (OS) of the whole population were 27.1 and 39.2%, respectively. The median follow-up duration was 27 months. The accuracy of PET/CT in metastatic lymph node detection was 72.7% (P = 0.005, 95% CI 0.583–0.871) and 81.8% (P = 0.011, 95% CI 0.635–0.990) in whole population and ICC subgroup analysis, respectively. SUV-max was shown by multivariate analysis to be an independent factor for DFS (P = 0.007 OR 1.16, 95% CI 1.04–1.29) and OS (P = 0.012 OR 1.145, 95% CI 1.030–1.273) after resection. SUV-max of 8 was shown to be a discriminant cut-off for poor oncological outcomes in patients with early cholangiocarcinoma (TNM stage I or II) after curative resection (3-year DFS: 21.2 vs. 63.2%, P = 0.004, and 3-year OS: 29 vs. 74% P = 0.048, respectively). Conclusion: PET/CT is a reliable imaging modality for metastatic lymph node detection in cholangiocarcinoma. Tumour SUV-max is an independent factor for oncological outcomes in patients with resectable disease. For patients who have TNM stage I or II cholangiocarcinoma, tumour SUV-max over 8 is associated with significantly inferior disease-free and overall survival even after curative resection. |
Persistent Identifier | http://hdl.handle.net/10722/259235 |
ISSN | 2023 Impact Factor: 2.3 2023 SCImago Journal Rankings: 0.772 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ma, KW | - |
dc.contributor.author | Cheung, TT | - |
dc.contributor.author | She, WH | - |
dc.contributor.author | Chok, KSH | - |
dc.contributor.author | Chan, ACY | - |
dc.contributor.author | Dai, WC | - |
dc.contributor.author | Chiu, WHK | - |
dc.contributor.author | Lo, CM | - |
dc.date.accessioned | 2018-09-03T04:03:39Z | - |
dc.date.available | 2018-09-03T04:03:39Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | World Journal of Surgery, 2018, v. 42 n. 3, p. 823-834 | - |
dc.identifier.issn | 0364-2313 | - |
dc.identifier.uri | http://hdl.handle.net/10722/259235 | - |
dc.description.abstract | Objectives: Role of 18-FDG PET/CT had been well established in other more prevalent malignancies such as colorectal and lung cancer; however, this is not as well defined in cholangiocarcinoma. Literature focusing on the prognostic values of preoperative PET/CT for resectable cholangiocarcinoma is scarce. Method: This is a retrospective cohort of 66 consecutive patients who had received curative resection for cholangiocarcinoma from 2010 to 2015. All patients had preoperative 18-FDG PET/CT performed. Accuracy of metastatic lymph node detection of PET/CT and the prognostic value of maximum standard uptake value (SUV-max) was explored. Results: There were 38 male and 28 female recruited, and the median age was 66. Intrahepatic cholangiocarcinoma (ICC) constituted the majority (59.1%) of the cases, followed by hilar cholangiocarcinoma (22.8%), gallbladder cancer (13.6%) and common bile duct cancer (4.5%). The 3-year disease-free survival (DFS) and overall survival (OS) of the whole population were 27.1 and 39.2%, respectively. The median follow-up duration was 27 months. The accuracy of PET/CT in metastatic lymph node detection was 72.7% (P = 0.005, 95% CI 0.583–0.871) and 81.8% (P = 0.011, 95% CI 0.635–0.990) in whole population and ICC subgroup analysis, respectively. SUV-max was shown by multivariate analysis to be an independent factor for DFS (P = 0.007 OR 1.16, 95% CI 1.04–1.29) and OS (P = 0.012 OR 1.145, 95% CI 1.030–1.273) after resection. SUV-max of 8 was shown to be a discriminant cut-off for poor oncological outcomes in patients with early cholangiocarcinoma (TNM stage I or II) after curative resection (3-year DFS: 21.2 vs. 63.2%, P = 0.004, and 3-year OS: 29 vs. 74% P = 0.048, respectively). Conclusion: PET/CT is a reliable imaging modality for metastatic lymph node detection in cholangiocarcinoma. Tumour SUV-max is an independent factor for oncological outcomes in patients with resectable disease. For patients who have TNM stage I or II cholangiocarcinoma, tumour SUV-max over 8 is associated with significantly inferior disease-free and overall survival even after curative resection. | - |
dc.language | eng | - |
dc.publisher | Springer New York LLC. The Journal's web site is located at http://link.springer.de/link/service/journals/00268/ | - |
dc.relation.ispartof | World Journal of Surgery | - |
dc.rights | The final publication is available at Springer via http://dx.doi.org/[insert DOI] | - |
dc.title | Diagnostic and prognostic role of 18-FDG PET/CT in the management of resectable biliary tract cancer | - |
dc.type | Article | - |
dc.identifier.email | Cheung, TT: cheung68@hku.hk | - |
dc.identifier.email | She, WH: brianshe@hku.hk | - |
dc.identifier.email | Chok, KSH: chok6275@hku.hk | - |
dc.identifier.email | Chan, ACY: acchan@hku.hk | - |
dc.identifier.email | Dai, WC: daiwc@HKUCC-COM.hku.hk | - |
dc.identifier.email | Chiu, WHK: kwhchiu@hku.hk | - |
dc.identifier.email | Lo, CM: chungmlo@hkucc.hku.hk | - |
dc.identifier.authority | Cheung, TT=rp02129 | - |
dc.identifier.authority | Chok, KSH=rp02110 | - |
dc.identifier.authority | Chan, ACY=rp00310 | - |
dc.identifier.authority | Chiu, WHK=rp02074 | - |
dc.identifier.authority | Lo, CM=rp00412 | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1007/s00268-017-4192-3 | - |
dc.identifier.pmid | 28905105 | - |
dc.identifier.scopus | eid_2-s2.0-85029448058 | - |
dc.identifier.hkuros | 288608 | - |
dc.identifier.volume | 42 | - |
dc.identifier.issue | 3 | - |
dc.identifier.spage | 823 | - |
dc.identifier.epage | 834 | - |
dc.identifier.isi | WOS:000424278600026 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 0364-2313 | - |